GlassScriptPhysician profile
Minxiang Gu
NPI 1154323376
$4,499.98
in general payments reported to CMS, 2019-2025
54 companies · $79.94 in 2025
The $79.94 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,866 · 2020: $1,350 · 2021: $669 · 2022: $343 · 2023: $112 · 2024: $81.09 · 2025: $79.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $353.17 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $347.31 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $317.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $290.94 | 2019-2025 | |
| Seagen INC. | $207.87 | 2019-2023 | Tukysa |
| Janssen Biotech, INC. | $190.35 | 2019-2024 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $182.99 | 2019-2020 | |
| Genzyme Corporation | $178.65 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $176.30 | 2019-2023 | Libtayo |
| Pfizer INC. | $167.27 | 2019-2023 | |
| Incyte Corporation | $145.02 | 2019-2021 | |
| Amgen INC. | $133.46 | 2019-2021 | |
| Emd Serono, INC. | $114.11 | 2019-2023 | Bavencio |
| Pharmacyclics LLC, An Abbvie Company | $111.45 | 2019-2022 | |
| Genentech USA, INC. | $107.94 | 2019-2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minxiang Gu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.